Hydatidiform Mole
9
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
44%
4 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
A Cohort Study of Hydatidiform Mole
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
RCT on the Efficacy of Methotrexate for the Prevention of GTD
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
The French National Reference Centre of GTD
A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole
A Trial for Patients With Gestational Trophoblastic Disease